Assessing Mortality Models in Systemic Sclerosis-Related Interstitial Lung Disease

被引:23
|
作者
Mango, Robert L. [1 ]
Matteson, Eric L. [1 ,2 ]
Crowson, Cynthia S. [1 ,2 ]
Ryu, Jay H. [3 ]
Makol, Ashima [1 ,4 ]
机构
[1] Mayo Clin Coll Med & Sci, Div Rheumatol, Rochester, MN 55905 USA
[2] Mayo Clin Coll Med & Sci, Dept Hlth Sci Res, Rochester, MN USA
[3] Mayo Clin Coll Med & Sci, Div Pulm & Crit Care Med, Rochester, MN USA
[4] Mayo Clin, Dept Internal Med, Div Rheumatol, 200 1st St SW, Rochester, MN 55905 USA
基金
美国国家卫生研究院;
关键词
Systemic sclerosis; Interstitial lung disease; Non-specific interstitial pneumonia; Usual interstitial pneumonia; Mortality modeling; IDIOPATHIC PULMONARY-FIBROSIS; SCLERODERMA LUNG; RISK PREDICTION; STAGING SYSTEM; SURVIVAL; TRIALS; SMOKING; PLACEBO; TRENDS; COHORT;
D O I
10.1007/s00408-018-0126-6
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
The gender, age, and lung physiology (GAP) model, interstitial lung diseases-GAP (ILD-GAP) model, and the smoking history, age, and diffusion capacity of the lung (SADL) model were compared using a systemic sclerosis-ILD (SSc-ILD) cohort to evaluate which best determined prognosis. The models were applied to a cohort of 179 patients with SSc seen at a tertiary care center within 1 year of ILD diagnosis. Demographics, clinical characteristics, and mortality were recorded. The performance of the models was assessed using standardized mortality ratios (SMR) of observed versus predicted outcomes for calibration and concordance (c)-statistics for discrimination. SSc-ILD patients with usual interstitial pneumonia (31, 17%) had a higher mortality than those with non-specific interstitial pneumonia (147, 83%) (hazard ratio 2.27; 95%CI 1.03-4.97). All 3 models had comparable discrimination (c = 0.72, 0.72, and 0.71, respectively). Regarding calibration, the ILD-GAP model underestimated mortality (SMR 1.50; 95%CI 1.05-2.14). Calibration was acceptable for SADL (SMR 1.00; 95%CI 0.70-1.44) and GAP (SMR 0.90; 95%CI 0.63-1.29). The SADL model underestimated mortality in Stage I ILD. The ILD-GAP model underestimated mortality, and the SADL model underestimated mortality in certain subgroups. However, the GAP model performed well in this cohort, providing the best prognostic information for SSc-ILD.
引用
收藏
页码:409 / 416
页数:8
相关论文
共 50 条
  • [41] Prognosis of patients with systemic sclerosis-related interstitial lung disease on the lung transplant waiting list: a retrospective study
    Nakayama, Yoichi
    Nakashima, Ran
    Handa, Tomohiro
    Ohsumi, Akihiro
    Yamada, Yoshito
    Nakajima, Daisuke
    Yutaka, Yojiro
    Tanaka, Satona
    Hamada, Satoshi
    Ikezoe, Kohei
    Tanizawa, Kiminobu
    Shirakashi, Mirei
    Hiwa, Ryosuke
    Tsuji, Hideaki
    Kitagori, Koji
    Akizuki, Shuji
    Yoshifuji, Hajime
    Date, Hiroshi
    Morinobu, Akio
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [42] Outcomes in Systemic Sclerosis-Related Lung Disease After Lung Transplantation
    Sottile, Peter D.
    Iturbe, David
    Katsumoto, Tamiko R.
    Connolly, M. Kari
    Collard, Harold R.
    Leard, Lorriana A.
    Hays, Steven
    Golden, Jeffrey A.
    Hoopes, Charles
    Kukreja, Jasleen
    Singer, Jonathan P.
    TRANSPLANTATION, 2013, 95 (07) : 975 - 980
  • [43] Prognosis of patients with systemic sclerosis-related interstitial lung disease on the lung transplant waiting list: a retrospective study
    Yoichi Nakayama
    Ran Nakashima
    Tomohiro Handa
    Akihiro Ohsumi
    Yoshito Yamada
    Daisuke Nakajima
    Yojiro Yutaka
    Satona Tanaka
    Satoshi Hamada
    Kohei Ikezoe
    Kiminobu Tanizawa
    Mirei Shirakashi
    Ryosuke Hiwa
    Hideaki Tsuji
    Koji Kitagori
    Shuji Akizuki
    Hajime Yoshifuji
    Hiroshi Date
    Akio Morinobu
    Scientific Reports, 13
  • [44] Short-Term Lung Function Changes and Predictors of Progressive Systemic Sclerosis-Related Interstitial Lung Disease
    Kaenmuang, Punchalee
    Navasakulpong, Asma
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2020, 83 (04) : 312 - 320
  • [45] PREDICTORS OF SURVIVAL IN PATIENTS WITH SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE ENROLLED IN THE SCLERODERMA LUNG STUDY II
    Volkmann, E.
    Tashkin, D.
    Fischer, A.
    Hoffmann-Vold, A. -M.
    Tseng, C. -H.
    LeClair, H.
    Khanna, D.
    Clements, P.
    Roth, M.
    Elashoff, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 534 - 534
  • [46] Quantifying Change In Pulmonary Function As a Prognostic Marker In Systemic Sclerosis-Related Interstitial Lung Disease.
    Moore, Owen
    Proudman, Susanna
    Goh, Nicole
    Corte, Tamera
    Rouse, Hannah
    Hennessy, Oliver
    Thakkar, Vivek
    Sahhar, Joanne
    Roddy, Janet E.
    Youssef, Peter
    Gabbay, Eli
    Nash, Peter
    Zochling, Jane
    Stevens, Wendy
    Nikpour, Mandana
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S289 - S289
  • [47] Quantitative computed tomography assessment for systemic sclerosis-related interstitial lung disease: comparison of different methods
    Ufuk, Furkan
    Demirci, Mahmut
    Altinisik, Goksel
    EUROPEAN RADIOLOGY, 2020, 30 (08) : 4369 - 4380
  • [48] Molecular targeted imaging biomarkers for personalized medicine strategies in systemic sclerosis-related interstitial lung disease
    Schniering, J.
    Benesova, M.
    Brunner, M.
    Feghali-Bostwick, C.
    Schibli, R.
    Distler, O.
    Mueller, C.
    Maurer, B.
    SWISS MEDICAL WEEKLY, 2017, 147 : 4S - 4S
  • [49] MOLECULAR TARGETED IMAGING BIOMARKERS FOR PERSONALIZED MEDICINE STRATEGIES IN SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE
    Schniering, J.
    Benesova, M.
    Brunner, M.
    Feghali-Bostwick, C.
    Schibli, R.
    Distler, O.
    Muller, C.
    Maurer, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 86 - 86
  • [50] Short- and Long-term Morbidity and Mortality Outcomes of African American Patients with Systemic Sclerosis-Related Interstitial Lung Disease
    Volkmann, Elizabeth
    Steen, Virginia
    Li, Ning
    Roth, Michael
    Clements, Philip
    Khanna, Dinesh
    Furst, Daniel
    Assassi, Shervin
    Kim, Grace
    Goldin, Jonathan
    Elashoff, Robert
    Tashkin, Donald
    ARTHRITIS & RHEUMATOLOGY, 2019, 71